Induction of immune responses in patients with b -
cell lymphoma against the surface - immunoglobulin idiotype expressed by their tumors
Not exact matches
Living in overcrowded conditions appears to protect children and young adults
against developing a particular type of Hodgkin
lymphoma (HL), a cancer that originates from the lymphocytes (white blood
cells).
Ronald Levy reports the first successful treatment of a patient with a monoclonal antibody
against the idiotype of a B
cell lymphoma.
As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in
lymphoma (shown by Dr. Allison to be effective
against melanoma), genetic engineering in
cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a
lymphoma idiotype.
One key weapon
against cancer is to supercharge T -
cells — the foot - soldiers of the immune system — to better detect and kill tumors, and a new trial at the Children's Research Institute has delivered promising results, keeping cases of Hodgkin's
lymphoma at bay for years at a time.
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use
against some types of large B -
cell lymphomas.
They were the first successful forms of immunotherapy for
lymphoma, with rituximab (Rituxan), a monoclonal antibody
against the CD20 target, now the standard of care for all B
cell lymphomas.